Instem (LSE:INS) Land And Improvements : £0.00 Mil (As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Instem Land And Improvements?

Instem's land and improvements for the quarter that ended in Jun. 2023 was £0.00 Mil.

Instem Land And Improvements Historical Data

The historical data trend for Instem's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instem Land And Improvements Chart

Instem Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Land And Improvements

Get a 7-Day Free Trial

Instem Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Instem Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Instem (LSE:INS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Instem PLC (LSE:INS) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

Diamond Way, Stone Business Park, Stone, Staffordshire, GBR, ST15 0SD

Website

https://www.instem.com

Instem PLC acts as a supplier of IT applications and technology-enabled outsourced services to the global health and life sciences community. Its segments include Study Management, Regulatory Solutions, and In Silico Solutions, Clinical Trial Acceleration. The company generates maximum revenue from Study Management. Geographically, it derives a majority of its revenue from the United States and also has a presence in the Europe and Rest of the World. Its portfolio of software solutions includes Instem Cloud, SEND Data Conversion, KnowledgeScan, SENDReady Consulting, Solution Deployment, Validation, Data Management, and Regulatory Information Management.

Instem (LSE:INS) Headlines

No Headlines